Ligand Pharmaceuticals Stock (NASDAQ:LGND)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$288.83

52W Range

$161.82 - $326.63

50D Avg

$296.71

200D Avg

$233.21

Market Cap

$5.77B

Avg Vol (3M)

$360.49K

Beta

0.98

Div Yield

-

LGND Company Profile


Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

47

IPO Date

Nov 18, 1992

Website

LGND Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 25Dec 24Dec 22
Service$6.81M$25.53M$1.12M
Intangible Royalty Assets$132.53M$95.33M-
Financial Royalty Assets$28.47M$13.44M-
Contract Revenue$66.87M$27.48M$19.22M
Royalty, Kyprolis$35.53M$38.38M$30.12M
Royalty, Evomela$5.94M$8.68M$10.20M
Royalty$161.00M$108.77M$72.53M
Material Sales, Captisol, Core$40.21M$30.88M$16.43M
License Fees$6.99M$1.94M$2.85M
Royalty, Other$10.37M$8.95M$7.63M
Material Sales, Captisol-$30.88M$104.50M
License Fees, Milestones, and Other Product, Other--$6.11M
Material Sales, Captisol, COVID--$88.07M
Milestone--$9.15M

Fiscal year ends in Dec 25 | Currency in USD

LGND Financial Summary


Dec 25Dec 24Dec 23
Revenue$268.09M$167.13M$131.31M
Operating Income$47.20M$-22.61M$11.94M
Net Income$124.45M$-4.03M$52.15M
EBITDA$158.96M$40.79M$100.84M
Basic EPS$6.44$-0.22$3.02
Diluted EPS$6.13$-0.22$2.94

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts


Q2 26Aug 06, 26 | 8:30 AM
Q1 26May 07, 26 | 8:30 AM
Q4 25Feb 26, 26 | 3:30 PM

Peer Comparison


TickerCompany
VKTXViking Therapeutics, Inc.
NAMSNewAmsterdam Pharma Company N.V.
ACADACADIA Pharmaceuticals Inc.
BLTEBelite Bio, Inc
ADMAADMA Biologics, Inc.
MIRMMirum Pharmaceuticals, Inc.
PRAXPraxis Precision Medicines, Inc.
DYNDyne Therapeutics, Inc.
CRNXCrinetics Pharmaceuticals, Inc.